Linked Life Data

21236562

Source:http://linkedlifedata.com/resource/pubmed/id/21236562

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21236562rdf:typepubmed:Citationlld:pubmed
pubmed-article:21236562lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:21236562lifeskim:mentionsumls-concept:C1705952lld:lifeskim
pubmed-article:21236562lifeskim:mentionsumls-concept:C0007102lld:lifeskim
pubmed-article:21236562lifeskim:mentionsumls-concept:C0385242lld:lifeskim
pubmed-article:21236562lifeskim:mentionsumls-concept:C1326205lld:lifeskim
pubmed-article:21236562lifeskim:mentionsumls-concept:C0334227lld:lifeskim
pubmed-article:21236562lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:21236562lifeskim:mentionsumls-concept:C1336646lld:lifeskim
pubmed-article:21236562lifeskim:mentionsumls-concept:C0056154lld:lifeskim
pubmed-article:21236562lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:21236562lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:21236562lifeskim:mentionsumls-concept:C2349975lld:lifeskim
pubmed-article:21236562lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:21236562pubmed:issue1lld:pubmed
pubmed-article:21236562pubmed:dateCreated2011-2-2lld:pubmed
pubmed-article:21236562pubmed:abstractTextThe present study indicated that the combination of TRAIL/Apo-2L and CA-4 exerted synergistic anti-proliferative effect against human colon carcinoma cells including SW-620 and HCT-116 in vitro. Moreover, the increased anti-tumor efficacy of TRAIL/Apo-2L combined with CA-4 was further validated on SW-620 xenograft model in nude mice. These enhanced anti-cancer activities were accompanied by caspase-mediated apoptosis. Furthermore, it was identified that NF-?B as the major determinant of TRAIL/Apo-2L resistance could be blocked in cytoplasm by TRAIL/Apo-2L plus CA-4 treatment. Taken together, these findings build the rationale for further (pre)clinical development of TRAIL/Apo-2L and CA-4 against colorectal cancer.lld:pubmed
pubmed-article:21236562pubmed:languageenglld:pubmed
pubmed-article:21236562pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21236562pubmed:citationSubsetIMlld:pubmed
pubmed-article:21236562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21236562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21236562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21236562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21236562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21236562pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21236562pubmed:statusMEDLINElld:pubmed
pubmed-article:21236562pubmed:monthMarlld:pubmed
pubmed-article:21236562pubmed:issn1872-7980lld:pubmed
pubmed-article:21236562pubmed:authorpubmed-author:ZhuHongHlld:pubmed
pubmed-article:21236562pubmed:authorpubmed-author:ZAKYYYlld:pubmed
pubmed-article:21236562pubmed:authorpubmed-author:WuRuiRlld:pubmed
pubmed-article:21236562pubmed:authorpubmed-author:HuYong-zhouYZlld:pubmed
pubmed-article:21236562pubmed:authorpubmed-author:HeQiao-junQJlld:pubmed
pubmed-article:21236562pubmed:authorpubmed-author:ZhangChongClld:pubmed
pubmed-article:21236562pubmed:authorpubmed-author:LinNeng-mingN...lld:pubmed
pubmed-article:21236562pubmed:authorpubmed-author:JiangHaiHlld:pubmed
pubmed-article:21236562pubmed:copyrightInfoCopyright © 2010 Elsevier Ireland Ltd. All rights reserved.lld:pubmed
pubmed-article:21236562pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21236562pubmed:day1lld:pubmed
pubmed-article:21236562pubmed:volume302lld:pubmed
pubmed-article:21236562pubmed:ownerNLMlld:pubmed
pubmed-article:21236562pubmed:authorsCompleteYlld:pubmed
pubmed-article:21236562pubmed:pagination11-9lld:pubmed
pubmed-article:21236562pubmed:meshHeadingpubmed-meshheading:21236562...lld:pubmed
pubmed-article:21236562pubmed:meshHeadingpubmed-meshheading:21236562...lld:pubmed
pubmed-article:21236562pubmed:meshHeadingpubmed-meshheading:21236562...lld:pubmed
pubmed-article:21236562pubmed:meshHeadingpubmed-meshheading:21236562...lld:pubmed
pubmed-article:21236562pubmed:meshHeadingpubmed-meshheading:21236562...lld:pubmed
pubmed-article:21236562pubmed:meshHeadingpubmed-meshheading:21236562...lld:pubmed
pubmed-article:21236562pubmed:meshHeadingpubmed-meshheading:21236562...lld:pubmed
pubmed-article:21236562pubmed:meshHeadingpubmed-meshheading:21236562...lld:pubmed
pubmed-article:21236562pubmed:meshHeadingpubmed-meshheading:21236562...lld:pubmed
pubmed-article:21236562pubmed:meshHeadingpubmed-meshheading:21236562...lld:pubmed
pubmed-article:21236562pubmed:meshHeadingpubmed-meshheading:21236562...lld:pubmed
pubmed-article:21236562pubmed:meshHeadingpubmed-meshheading:21236562...lld:pubmed
pubmed-article:21236562pubmed:meshHeadingpubmed-meshheading:21236562...lld:pubmed
pubmed-article:21236562pubmed:meshHeadingpubmed-meshheading:21236562...lld:pubmed
pubmed-article:21236562pubmed:meshHeadingpubmed-meshheading:21236562...lld:pubmed
pubmed-article:21236562pubmed:meshHeadingpubmed-meshheading:21236562...lld:pubmed
pubmed-article:21236562pubmed:meshHeadingpubmed-meshheading:21236562...lld:pubmed
pubmed-article:21236562pubmed:meshHeadingpubmed-meshheading:21236562...lld:pubmed
pubmed-article:21236562pubmed:meshHeadingpubmed-meshheading:21236562...lld:pubmed
pubmed-article:21236562pubmed:meshHeadingpubmed-meshheading:21236562...lld:pubmed
pubmed-article:21236562pubmed:year2011lld:pubmed
pubmed-article:21236562pubmed:articleTitleEnhanced anti-tumor activity by the combination of TRAIL/Apo-2L and combretastatin A-4 against human colon cancer cells via induction of apoptosis in vitro and in vivo.lld:pubmed
pubmed-article:21236562pubmed:affiliationInstitute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.lld:pubmed
pubmed-article:21236562pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21236562pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed